some considerations about cardiac toxicity of combination therapy for chronic hepatitis c

نویسندگان

reza karbasi-afshar cardiovascular diseases department, baqiyatallah university of medical sciences, tehran, ir iran

amin saburi chemical injuries research center, baqiyatallah university of medical sciences, tehran, ir iran; baqiyatallah research center of gastroenterology and liver diseases (brcgl), baqiyatallah university of medical sciences, tehran, ir iran; chemical injuries research center and baqiyatallah research center of gastroenterology and liver diseases (brcgl), baqiyatallah university of medical sciences, mollasadra st, vanaksq, tehran, ir iran. tel/fax: +98-2188600067

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Some Considerations About Cardiac Toxicity of Combination Therapy for Chronic Hepatitis C

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. We read with great interest the recently published article by Almawardy et al entitled " Is Combination Therapy for Chronic Hepatitis C Toxic for Cardiac Function? " (1). They skillfully evaluated 120 cases with hepatitis C virus infections treated with a combination proto...

متن کامل

EFFICACY AND SAFETY OF COMBINATION THERAPY OF INTERFERON-ALPHA 2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C

Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand of IFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition of RIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monother...

متن کامل

is combination therapy for chronic hepatitis c toxic for cardiac function?

background many types of cardiovascular complications such as; cardiac arrhythmias, impaired cardiac function, myocardial ischemia and decreased left ventricular function, have been attributed to interferon therapy. objectives the aim of this study was to evaluate the effects of combination therapy pegylated interferon and ribavirin on left ventricular systolic and diastolic functions in patien...

متن کامل

Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C

OBJECTIVE To explore the expected long-term health and economic outcomes of telaprevir (TVR) plus peginterferon alfa-2a and ribavirin (PR), a regimen that demonstrated substantially increased sustained virologic response (SVR) compared with PR alone in adults with chronic genotype 1 hepatitis C virus (HCV) and compensated liver disease in the Phase III studies ADVANCE (treatment-naïve patients)...

متن کامل

Is Combination Therapy for Chronic Hepatitis C Toxic for Cardiac Function?

BACKGROUND Many types of cardiovascular complications such as; cardiac arrhythmias, impaired cardiac function, myocardial ischemia and decreased left ventricular function, have been attributed to interferon therapy. OBJECTIVES The aim of this study was to evaluate the effects of combination therapy pegylated interferon and ribavirin on left ventricular systolic and diastolic functions in pati...

متن کامل

efficacy and safety of combination therapy of interferon-alpha 2b plus ribavirin for chronic hepatitis c

introduction: the aim of this study is to assess the therapeutic efficacy and safety of a particular brand of ifn alpha (pdferon b®) in combination with ribavirin (rlba) on iranian patients with chronic hepatitis c (chc). the addition of riba to the standard treatment with interferon (ifn) alpha led to an improvement in sustained virologic response (svr) from less than 20% with ifn monotherapy ...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
hepatitis monthly

جلد ۱۳، شماره ۵، صفحات ۰-۰

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023